VirtualScopics Inc

VirtualScopics — Shareholder Meeting (May 2010)

54 slides from VirtualScopics's shareholder meeting presentation, May 27, 2010

  1. Slide 1: Annual Stockholders' Meeting

    Annual Stockholders’ Meeting May 27, 2010 q . KY VIRTUALSCOPICS

  2. Slide 2: Presentation Overview

    Presentation Overview f " = &§ | Business Overview i * Jeff Markin/Molly Henderson Proxy Tally and Results Robert Klimasew: VIRTUALSCOPICS VirtwolScopics Al Rights Reserved ow more. Move fester:

  3. Slide 3: 2010 Proxy Summons

    2010 Proxy Summons Election of Board of Directors for 2010/2011 - Mostafa Analoui Dan Kerpelman Robert Klimasewski - Sidney Knafel Jeffrey Markin Norman Mintz Charles Phelps Terence Walts Ratify the appointment of Marcum LLP as independent financial statement auditors for the fiscal year ended Decem

  4. Slide 4: Presentation Overview

    Presentation Overview f " = &§ | Business Overview i * Jeff Markin/Molly Henderson Proxy Tally and Results Robert Klimasew: VIRTUALSCOPICS VirtwolScopics Al Rights Reserved ow more. Move fester:

  5. Slide 5: Safe Harbor

    SAFEHARBOR This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achiev

  6. Slide 6: Business Overview

    a . ‘ ¥ VIRTUALSCOPICS | Business Overview _ “| Jeff Markin President and CEO

  7. Slide 7: The Many Perspectives of VirtualScopics

    The Many Perspectives of VirtualScopics

  8. Slide 8: Key Company Highlights

    VirtualScopics imaging for aca trials Key Company Highlights + Integrated solution delivered as a series of services that manage imaging trials from inception to FDA submission. + Highly automated quantitative analysis vs. conventional qualitative radiologist driven analysis. + Very precise measurem

  9. Slide 9: Therapeutic Areas

    Therapeutic Areas bee) ONCOlOGY Erna RD ‘oe resi ome 20 US) ue Volume (US) siren Us) Central Nervous [ Central Nervous System | {han WGM Vane, an arena acon [ osteoarthritis _| is ‘ee ra” Tissue Quatty (2, dGEMRIC) Muscle Wasting “Wasce Vourme for taghiea * invamuseular ft Volume for highest * Subcu

  10. Slide 10: Global map

    Global map a ¥ VIRTUALSCOPICS Know more Move fester:

  11. Slide 11: Yi vixrvaisconics

    Os =) Yi vixrvaisconics om ore Move se.

  12. Slide 12: Competitive Landscape

    Competitive Landscape Oncology BioClinica Late Phase Perceptive Informatics Full Icon(Imaging) Full Synarc 1986 _|Muskuloskeletal] $90M * Very good set of competitors * Much larger or are part of much larger companies * In business longer than VirtualScopics VIRTUALSCOPICS

  13. Slide 13: Differentiated high value position

    oe e £ 2 3 ES &: 2 = s 8 Position of strength ir janizational capability! Differentiated high value position for VirtualScopic: VIRTUALSCOPICS VitualScopics All Rights Reserved w mere: Move fester

  14. Slide 14: Competitor Comment

    Competitor Comment t The CEO of one of our larger Competitors told me * “You must be very proud of your team and the financial performance you have delivered in 2009. While our business and others like us have been flat to declining due to the global business slowdown you (VirtualScopics) have seen

  15. Slide 15: Yi vixrvaisconics

    Os =) Yi vixrvaisconics om ore Move se.

  16. Slide 16: Core Competencies

    Core Competencies and processes through the use of medical imaging and imaging science To manage and process very large == quantities of information quickly and = efficiently in a flexible and transparent manner VIRTUALSCOPICS

  17. Slide 17: Imaging

    Imaging © Proprietary automated rao image quantification software © Expertise in image-based biomark Virwalscopis FOAL RALGresinay eis “Nomarces relevance to disease Software Medicine Image Analysis Service —— ¥ VIRTUALSCOPICS VirtuolScopies Al Rights Reserved

  18. Slide 18: Operational Strategy

    Operational Strategy Invest in the capabilities of our employees as the foundation for success Deploy Lean principles and Six Sigma tools as corporate methodology to: cale operations efficiently Enable flexibility and rapid response to changing customer ~ a priorities ¥ VIRTUALSCOPICS.

  19. Slide 19: Lean & Six Sigma Tactics

    Lean & Six Sigma Tactics Track and monitor performance metrics as Proactively scale operations efficiently capacity confirmation of progress pees ‘* Enables rapid response to ‘* Enable surge capacity when ‘changing customer fede for changing client requirements needs ‘mapping approach as itis system

  20. Slide 20: The VirtualScopics Oncology Promise

    The VirtualScopics Oncology Promise “NirtualScopics pledges to provide quality image-based biomarker deliveries according to approved specifications while adhering to our customers’ contractual timelines. If this promise is not met, the applicable analysis and/or delivery fee will be credited.” In o

  21. Slide 21: Yi vixrvaisconics

    Os =) Yi vixrvaisconics om ore Move se.

  22. Slide 22: Project Backlog

    Project Backlog ¢ 29 Customers ¢ Approximately 135 individual projects ¢ Representing 7 disease areas ¢ Both Animal and human studies Broad based and built upon strong foundation! a ¥ VIRTUALSC

  23. Slide 23: Studies Since Inception

    ‘Studies Since Inception Ab | Phase1 Phase2 Phase3 Phase 4

  24. Slide 24: Customer Experiences

    Customer Experiences Customer 1

  25. Slide 25: YF viervaiscones

    YF viervaiscones Seeing potentially interesting indi h idy | asked VS to. lo see VIRTUALSCOPICS w mere: Move fester VitualScopics All Rights Reserved

  26. Slide 26: Customer

    Customer 2 VY vixruaisconics Company wanted to determine efficacy before moving two drugs into Asked mani VIRTUALSCOPICS w mere: Move fester VitualScopics All Rights Reserved

  27. Slide 27: Customer

    Customer 3 VIRTUALSCOPICS

  28. Slide 28: Value Proposition to Drug Developers

    Value Proposition to Drug D p + Higher precision = fewer patients + Fewer patients = lower trial costs + Smaller trial sizes = quicker enrollment and faster s + Algorithm driven analysis yields results faster than jologists driven analysis Better information for Go-No Go decisions ~ + Enhanced chara

  29. Slide 29: Yi vixrvaisconics

    oe Yi vixrvaisconics om ore Move se.

  30. Slide 30: VitualScopics All Rights Reserved

    VitualScopics All Rights Reserved

  31. Slide 31: Employment

    Employment Age of Employees Years of Service al | i. ltha 2029 30894049 506060 Number Number Lessthan 1-2 year 3years S6years 7-9 years year 76 Employees, 50% increase over 2009 Very diverse from an age perspective Good mix of long term and new employees VIRTUALSCOPICS

  32. Slide 32: Comments by Local Business Leaders

    Comments by local 2 Local Business Leaders A prominent local investment company leader and senior manager at the University said the following: While it is important for VirtualScopics to be successful for investors it is more important for VirtualScopics to be successful for Rochester! VIRTUALSCOPI

  33. Slide 33: Yi vixrvaisconics

    Os =) Yi vixrvaisconics om ore Move se.

  34. Slide 34: Financial & Strategic Overview

    a . : . ¥ VIRTUALSCOPICS | Financial & Strategic Know more. Move faster. = Overview é O ee) Molly Henderson Chief Business & Financial Officer Sr. Vice President

  35. Slide 35: 2009 Financial Guidance

    2009 Financial Guidance Ao Beginning of Year Guidance Actual Revenues $9-10 million $10.4 million Full year gross margin 50% 54% Full year Adjusted EBITDA preakeven $1.2 million (cash) Full Year 2009 Results: + 45% increase in full-year revenues + 81% increase in full-year gross profit “Adjusted EBI

  36. Slide 36: Revenues & Gross Profit

    Revenues & Gross Pro’ — Quarterly Trends e} he] Annual Revenues Annual Gross Profit ane = — Cust $3,000,000. $y $4,000,000 $2,000,000 — — Ye | - 2005 20072008. 2009 Steady growth in 4x increase in 4x increase in Since inception in revenues in 4 gross profit in 4 1, over race ae years, > 100% years,

  37. Slide 37: Adjusted EBITDA — Quarterly Trend

    Adjusted EBITDA* — Quarterly Trend Annual Adjusted EBITDA 1.500000 Adjusted EBITDA improved $1,000 000 3500000 & 2009, Revenues increased +(300,000) $3MM over the same $1,000,000), riod SHE Strong cost controls and solid economies of scale (2,000,000) $2,500,000) VIRTUALSCOPICS Know mere. Move ster

  38. Slide 38: Project Balance (Backlog)

    Project Balance (Backlog) 345,000,000 $40,000,000 $35,000,000 20900200 25900200 contracted Moteslae awarded 525000000 — 19900000 - $5,000,000 2005 2006 2007 2008 2/4/2010 - February 2010 — Backlog of $41,000,000, ~70% increase over prior year + Total backlog increased 70% in 14 mos., 17x increase in

  39. Slide 39: 2010 Financial Guidance

    2010 Financial Guidance Financial Area 2010 Guidance | Revenues $13 million | Full year gross margin | 50% Full year Adjusted EBITDA (cash) $1.5 million (First quarter 2010 results: -Revenue increased 44% (60% on recurring revenues) Gross profit increased 43% -Operating income improved $500,000 3,00

  40. Slide 40: Blood perfusion and vascularity using DCE-MRI

    Blood perfusion and vascularity using DCE-MRI (dynamic contrast enhanced MRI) t Week 4 Week 8 is requires 2 months Provides time for Oncologist/Patient to alter treatment plans if no response is seen VS software tools used on over 30 clinical trials of anti-angiogenic drugs Broader applicability wit

  41. Slide 41: Value Proposition

    Value Proposition meg oncologists/Patients a * Early response determination to therapy * Allows time to alter treatments CS * Assurance that expensive therapy is working * Avoidance of paying for pricey ineffective compounds Pharmaceutical companies: * Companion diagnostic/drive market share a ¥ VIR

  42. Slide 42: Personalized Medicine Application

    Personalized Medicine Application [ Product concept el Market/Application strategy ¢ Phase | ¢ Phase Il © Phase III e Launch a ») VIRTU, VitolScapes A Rights Resorved

  43. Slide 43: Personalized Medicine — Phase I

    Personalized Medicine — Phase | i (| S| Fa Phase d data r and in ‘Impacted groups and related value proposition ‘Local focus group sessions (Oncologists and Payers) . cna forces and threats technologies ‘* Product concept/technology/summ era an + Regulator . Frrinranen landscape + Operational matter

  44. Slide 44: Personalized Medicine — Phase II

    Personalized Medicine Phase II — a ¢ Begin regulatory process ¢ Identify/engage commercialization and market experts ¢ Summarize findings/final assessment ¢ Capital requirement assessment ¢ Explore/define/develop go to market strategy ae ¥ VIRTUALSCOPICS

  45. Slide 45: Phase II: Commercialization Assessment

    Phase II: Cc cialization A \mercialization ex} Identify/e * Deep dive technology assessment. * Quality of results/data * Positive and negative predictive values * Adoption requirements research/focus groups with KOLs and decision makers _ within Payer group + Market readiness + Feasibility ‘+ Market

  46. Slide 46: Personalized Medicine — Phase III

    Personalized Medicine Phase III rT ¢ Obtain regulatory approval ¢ Reimbursement process ¢ Operational preparedness © Obtain capital, if required ¢ Execute go to market strategy e Launch

  47. Slide 47: VirtualScopics Strategic Planning

    VirtualScopics Strategic Planning t How best will we capitalize on our assets and how will we define success? q * Strategic planning sessions conducted Q4 of 2009 * Identified strengths, weaknesses, opportunities and threats * Strong look at value proposition, industry dynamics, competing technologi

  48. Slide 48: To improve the lives of those impacted by disease and disability

    To improve the lives of those impacted by disease and disability VirtwolScopics Al Rights Reserved

  49. Slide 49: Decision making

    cision making + Flexible, efficient and quality operating systems * Scientific and operational excellence focused on collaboration and responsiveness * Employees that work in an environment that inspires them to be the best VIRTUALSCOPICS ow more. Move fester: VirtwolScopics Al Rights Reserved

  50. Slide 50: How We Will Succeed

    How We Will Succeed Clinical Trial Market * Currently only have ~5% of market, * Real-time access to critical information to enable immediate and accurate decisions by our customers * Broader globalization * Channeling and partnering opportunities * Decision support software enabling oncologists to

  51. Slide 51: VSCP: Year in Review

    VSCP: 1 Year L lk walk sila 2009 stock price increased 100% ed 400% over 12 month average Volume incre: 550% increase over past 6 months ¥ VIRTUALSCOPICS VitualScopics AU Rights Reserved now more. Move aster

  52. Slide 52: Capitalization

  53. Slide 53: VirtualScopics: years ago an idea. Today a reality...

    VirtualScopics 10 years ago an idea. Today a reality... ¢ Profitable company * Publicly traded on Nasdaq * Working with the largest pharmaceutical companies in the world ¢ Helping get the right drugs to market sooner © Impacting the lives of those impacted by disease a ¢ VIRTUALSCOPICS

  54. Slide 54: Thank You

    ale Thank You Question and Answer g 5 ¥ VIRTUALSCOPICS

VirtualScopics — Shareholder Meeting (May 2010) on 6ix